NDAC
This article was originally published in The Rose Sheet
Executive Summary
Eric Brass, MD/PhD, Harbor-UCLA Medical Center, became acting chair of the FDA advisory committee and heir apparent upon the four- year term expiration of former Chair Ralph D'Agostino, PhD, Boston University. D'Agostino, whose term expired May 31, continues to participate in the committee as a consultant who may vote on issues on a meeting-by-meeting basis, most recently during the discussions on health care antiseptics ("The Rose Sheet" July 27, p. 8). If Brass is to be the successor, his nomination likely will be approved in about two months, along with nominations to replace three other committee vacancies. Three other NDAC members' terms are in May 1999 and three more in May 2000...